Recursion Pharmaceuticals Stock Earnings Reports

Recursion Management reiterated its focus on translating AI-driven discovery into repeatable, product-focused drug development. The company highlighted clinical progress across multiple wholly owned programs and partner collaborations: REC-4881 (allosteric MEK1/2 inhibitor) has shown a meaningful reduction in precancerous polyps in FAP and FDA engagement is underway toward a potential registrational path; REC-1245 (an RBM39 degrader) reported early Phase I safety and PK from 16 patients with no dose-limiting toxicities and PD evidence of target engagement, with additional dose-escalation and fuller PK/PD data expected in H2; REC-4539 (an LSD1 inhibitor) has dosed its first patient in Phase I with the molecule designed to limit thrombocytopenia and be brain-penetrant. Platform advances include published transcriptomics models (TxPert and TxFM) and claims of substantial efficiency gains in discovery (synthesizing ~90% fewer compounds vs. industry benchmarks and ~2x faster progression to development candidates), faster trial enrollment from ClinTech capabilities (30–60% faster), and a proprietary multimodal data moat (>50 PB). Partnerships have generated >$500M in inflows and delivered 10 milestones to date, with ongoing collaboration milestones (Sanofi, Roche/Genentech) potentially producing opt-ins or development candidates in the next 12–18 months. Financially, Recursion reported $665M cash and equivalents, expects runway into early 2028 without additional financing, has reduced cash operating expenses ~30% YoY, and maintains 2026 cash OPEX guidance of < $390M. The company emphasized continued disciplined capital allocation, a cadence of clinical readouts across all clinical-stage programs over the next 12–18 months, and further platform-driven improvements to target selection, chemistry, and clinical design.